GLP1R and type 2 diabetes mellitus: Results of cardiovascular outcome trials (CVOTs) prompted recommendations to prioritize two classes of glucose lowering medications (GLM) for secondary prevention of MACE in people with T2D, namely glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) [2].